KLĀRITOS is a novel managed-care company specializing in precision medicine. The Company has developed a proprietary, disruptive healthcare delivery model to address the critical inefficiencies in the current U.S. healthcare system with regard to specialty drugs spending. This integrated model consists of a novel treatment paradigm and an efficient drug distribution, payment, and pricing system.
This model provides significant value propositions to all stakeholders: patients, employers, pension funds, and payers. The Company offers both therapeutic efficacy and financial assurances for FDA-approved therapies on a disease-specific basis.
The Company is well positioned to scale its proprietary platform to autoimmune diseases, inflammatory disorders, and cancers. Our initial focus is on autoimmune (e.g., rheumatoid arthritis) and inflammatory disorders (e.g., Crohn's disease) as this is the single biggest drug spending area for pension funds and employers in the U.S.
KLĀRITOS provides clarity in treatment, distribution, payment, and pricing.
Several specialty drugs are developed in recent years to treat cancers, autoimmune diseases, and rare disorders. Some are curative. 225 new specialty drugs would enter market by 2021.
A vast majority of these drugs cost over $100,000 per patient-per year. A significant percentage of eligible patients in the U.S. cannot afford these expensive therapies.
Drug spending in the U.S. will grow to $590 B by 2020, up from $337 B in 2015.
Treating patients with cancers and chronic diseases, and managing the associated short- and long-term disabilities will become an unsustainable proposition for employers, pension funds, and payers in the U.S.